These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 15202574)

  • 1. Development of oral controlled-release tablet formulations based on diltiazem-carrageenan complex.
    Bonferoni MC; Rossi S; Ferrari F; Caramella C
    Pharm Dev Technol; 2004; 9(2):155-62. PubMed ID: 15202574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of complex solubility on formulations based on lambda carrageenan and basic drugs.
    Aguzzi C; Bonferoni MC; Fortich MR; Rossi S; Ferrari F; Caramella C
    AAPS PharmSciTech; 2002; 3(3):E27. PubMed ID: 12916942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of a diltiazem-lambda carrageenan complex.
    Bonferoni MC; Rossi S; Ferrari F; Bettinetti GP; Caramella C
    Int J Pharm; 2000 May; 200(2):207-16. PubMed ID: 10867250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factorial analysis of the influence of dissolution medium on drug release from carrageenan-diltiazem complexes.
    Bonferoni MC; Rossi S; Ferrari F; Stavik E; Pena-Romero A; Caramella C
    AAPS PharmSciTech; 2000 Jun; 1(2):E15. PubMed ID: 14727848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug release kinetics and front movement in matrix tablets containing diltiazem or metoprolol/λ-carrageenan complexes.
    Bettini R; Bonferoni MC; Colombo P; Zanelotti L; Caramella C
    Biomed Res Int; 2014; 2014():671532. PubMed ID: 25045689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design of floating bilayer tablets of diltiazem hydrochloride and lovastatin.
    Kulkarni AS; Bhatia MS
    PDA J Pharm Sci Technol; 2008; 62(5):344-52. PubMed ID: 19055230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative studies on polyelectrolyte complexes and mixtures of chitosan-alginate and chitosan-carrageenan as prolonged diltiazem clorhydrate release systems.
    Tapia C; Escobar Z; Costa E; Sapag-Hagar J; Valenzuela F; Basualto C; Gai MN; Yazdani-Pedram M
    Eur J Pharm Biopharm; 2004 Jan; 57(1):65-75. PubMed ID: 14729081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Formulation, in vitro evaluation and study of variables on tri-layered gastro-retentive delivery system of diltiazem HCl.
    Raut Desai S; Rohera BD
    Drug Dev Ind Pharm; 2014 Mar; 40(3):380-9. PubMed ID: 23369093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Controlled-release tablet matrices from carrageenans: compression and dissolution studies.
    Hariharan M; Wheatley TA; Price JC
    Pharm Dev Technol; 1997 Nov; 2(4):383-93. PubMed ID: 9552467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modified release from hydroxypropyl methylcellulose compression-coated tablets.
    Rujivipat S; Bodmeier R
    Int J Pharm; 2010 Dec; 402(1-2):72-7. PubMed ID: 20883759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Studies in release behavior of diltiazem HCl from matrix tablets containing (hydroxypropyl)methyl cellulose and xanthan gum.
    Gohel MC; Amin AF; Patel KV; Panchal MK
    Boll Chim Farm; 2002; 141(1):21-8. PubMed ID: 12064053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and in vitro evaluation of an oral floating matrix tablet formulation of diltiazem hydrochloride.
    Gambhire MN; Ambade KW; Kurmi SD; Kadam VJ; Jadhav KR
    AAPS PharmSciTech; 2007 Sep; 8(3):E73. PubMed ID: 17915823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Formulation development and evaluation of Diltiazem HCl sustained release matrix tablets using HPMC K4M and K100M.
    Qazi F; Shoaib MH; Yousuf RI; Qazi TM; Mehmood ZA; Hasan SM
    Pak J Pharm Sci; 2013 Jul; 26(4):653-63. PubMed ID: 23811439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of pH and ionic strength of dissolution media on in-vitro release of two model drugs of different solubilities from HPMC matrices.
    Asare-Addo K; Conway BR; Larhrib H; Levina M; Rajabi-Siahboomi AR; Tetteh J; Boateng J; Nokhodchi A
    Colloids Surf B Biointerfaces; 2013 Nov; 111():384-91. PubMed ID: 23850747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of ethylcellulose as matrices for controlled release drug delivery.
    Quadir MA; Chanda E; Haider SS; Reza MD; Datta BK
    Pak J Pharm Sci; 2005 Apr; 18(2):29-34. PubMed ID: 16431395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of modified release diltiazem HCl tablets using composite index to identify optimal formulation.
    Gohel MC; Patel MM; Amin AF
    Drug Dev Ind Pharm; 2003 May; 29(5):565-74. PubMed ID: 12779286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral controlled release formulations of rifampicin. Part II: Effect of formulation variables and process parameters on in vitro release.
    Hiremath PS; Saha RN
    Drug Deliv; 2008; 15(3):159-68. PubMed ID: 18379928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro--in vivo evaluation of tableted caseinchitosan microspheres containing diltiazem hydrochloride.
    al-Suwayeh SA; el-Helw AR; al-Mesned AF; Bayomi MA; el-Gorashi AS
    Boll Chim Farm; 2003; 142(1):14-20. PubMed ID: 12680034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug release kinetic analysis and prediction of release data via polymer molecular weight in sustained release diltiazem matrices.
    Adibkia K; Ghanbarzadeh S; Mohammadi G; Khiavi HZ; Sabzevari A; Barzegar-Jalali M
    Drug Res (Stuttg); 2014 Mar; 64(3):118-23. PubMed ID: 23986307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and in-vitro evaluation of modified release tablets including ethylcellulose microspheres loaded with diltiazem hydrochloride.
    Sengel CT; Hasçiçek C; Gönül N
    J Microencapsul; 2006 Mar; 23(2):135-52. PubMed ID: 16754371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.